US industry hails House committee hard line on user fee bill
This article was originally published in Clinica
US industry association AdvaMed has applauded the House energy and commerce health committee for its passage late last week of the user fee bill (MDUFMA), and especially for its removal of a proposal to limit the pre-emptive effect of the FDA's device-specific actions. This would have potentially created hundreds of standards for medical technology manufacturers, said AdvaMed president and CEO Stephen Ubl.
You may also be interested in...
Aker BioMarine seeks supplement firms to use its EPA/DHA innovation bound by lysophosphatidylcholine to enable the fatty acids to pass through the blood-brain and blood-retinal barriers and boost of eye and brain health benefits. It will submit an NDI notificaion in the US during 2022.
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Commissioner Hahn’s tweet announcing a return to inspections, while not a new policy, may be signal that FDA understands sponsor concerns with the agency’s limited ability to conduct onsite inspections. Effort may be aimed at reassuring industry even as CRLs related to manufacturing increase.